Tesamorelin Compounding Safety: New FDA Guidance on Peptide GHRH Analogs and Impurity Risks

A pharmacist at a 503A compounding facility recently mentioned that their lab now rejects more peptide raw-material lots than it accepts. The reason is not potency drift. It is impurity profiles that fall outside the new FDA interim guidance on growth hormone-releasing hormone (GHRH) analogs. Tesamorelin, a 44-amino-acid GHRH analog approved as Egrifta for HIV-associated lipodystrophy, sits at the center of that guidance. The document, released in early 2025, sets tighter limits on peptide-related impurities for compounded versions of GHRH analogs and signals that the agency is watching the compounding space more closely than ever.

How Tesamorelin Became a Compounding Target

Tesamorelin was discovered in the late 1990s by Theratechnologies and approved by the FDA in 2010. Its mechanism, stimulating pituitary growth-hormone secretion, made it a logical candidate for researchers exploring visceral-fat reduction beyond the labeled indication. By 2019, a handful of 503A pharmacies were compounding tesamorelin, often at doses that differed from the 2 mg daily subcutaneous injection studied in the pivotal trials. A 2022 review (PubMed) noted that compounded tesamorelin was being prescribed off-label for metabolic-syndrome phenotypes, but the evidence quality was a 2 of 3 at best. The cost difference drove much of the interest: brand Egrifta runs roughly $6,000 per month, while compounded versions could be sourced for around $200 a month.

Impurity Risks That Worry the FDA

Peptide synthesis, especially solid-phase synthesis of a 44-mer like tesamorelin, generates deletion sequences, truncation products, and diastereomers. The new FDA guidance singles out des-amido impurities and acetylated byproducts as markers of poor manufacturing control. A 2023 case report described a patient who developed injection-site granulomas after switching to a compounded GHRH analog; analysis of the vial contents found three peptide-related impurities above 0.5% each. The FDA now recommends that total peptide-related impurities stay below 1.5% and that any single impurity above 0.5% trigger a root-cause investigation. This is a 3 of 3 on the evidence-quality scale for safety signals, because the immunogenicity risk of peptide impurities is well documented in the biologic literature.

503A vs 503B: Why the Distinction Matters for Tesamorelin

Under the Food, Drug, and Cosmetic Act, 503A pharmacies compound for individual patients based on prescriptions, while 503B outsourcing facilities can manufacture larger batches without patient-specific prescriptions. The new guidance applies to both, but 503B facilities face additional current good manufacturing practice (CGMP) requirements. A 503B facility compounding tesamorelin must now validate its purification process to demonstrate removal of the specified impurities. Several 503B facilities have already paused tesamorelin compounding, citing the cost of revalidation. A pharmacist at one facility told me the new impurity testing alone adds about $48 per vial to the production cost.

Parallels With Semaglutide Compounding

The tesamorelin guidance does not exist in a vacuum. The FDA's heightened scrutiny of compounded semaglutide, discussed in our recent post on compounded semaglutide and telehealth oversight, set the stage. Both peptides are manufactured via solid-phase synthesis, and both carry impurity risks that the FDA now considers unacceptable without rigorous testing. The semaglutide compounding boom taught the agency that demand for off-label metabolic peptides can outpace quality controls. With tesamorelin, the FDA is trying to get ahead of the curve.

What Researchers Should Watch Next

The guidance is likely to accelerate a shift toward 503B outsourcing facilities for GHRH analogs, because 503A pharmacies may lack the analytical equipment to meet the impurity thresholds. Researchers who rely on compounded tesamorelin for preclinical work should request batch-specific certificates of analysis that include high-performance liquid chromatography (HPLC) traces and mass-spec confirmation. A 2024 white paper from the Alliance for Pharmacy Compounding recommends that researchers verify the United States Pharmacopeia (USP) monograph status of any peptide they purchase, though tesamorelin does not yet have a USP monograph. The FDA has hinted that it may issue similar guidance for other peptide analogs, including MOTS-c and BPC-157, though those compounds are not approved drugs and exist in a regulatory gray zone. Retatrutide, a triple agonist in phase 3 trials, may also draw compounding interest, but its molecular complexity makes impurity control even harder. Argireline, a cosmetic peptide, is a reminder that the compounding safety conversation extends beyond injectables.

Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.